Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies...
December 02, 2025 16:01 ET | Source: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 20, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics to Participate in Upcoming Investment Conferences
November 13, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
November 12, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
November 06, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
November 06, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces $23 Million Registered Direct Offering
November 04, 2025 16:01 ET | Source: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
October 14, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference